OBJECTIVE: This study determined the feasibility and efficacy of an automated proportional-integral-derivative with insulin feedback (PID-IFB) controller in overnight closed-loop (OCL) control of children and adolescents with type 1 diabetes over multiple days in a diabetes camp setting. RESEARCH DESIGN AND METHODS: The Medtronic (Northridge, CA) Android™ (Google, Mountain View, CA)-based PID-IFB system consists of the Medtronic Minimed Revel™ 2.0 pump and Enlite™ sensor, a control algorithm residing on an Android phone, a translator, and remote monitoring capabilities. An inpatient study was completed for 16 participants to determine feasibility. For the camp study, subjects with type 1 diabetes were randomized to either OCL or sensor-augmented pump therapy (control conditions) per night for up to 6 nights at diabetes camp. RESULTS: During the camp study, 21 subjects completed 50 OCL nights and 52 control nights. Based on intention to treat, the median time spent in range, from 70 to 150 mg/dL, was greater during OCL at 66.4% (n = 55) versus 50.6% (n = 52) during the control period (P = 0.004). A per-protocol analysis allowed for assessment of algorithm performance with the median percentage time in range, 70-150 mg/dL, being 75.5% (n = 37) for OCL versus 47.6% (n = 32) for the control period (P < 0.001). There was less time spent in the hypoglycemic ranges <60 mg/dL and <70 mg/dL during OCL compared with the control period (P = 0.003 and P < 0.001, respectively). CONCLUSIONS: The PID-IFB controller is effective in improving time spent in range as well as reducing nocturnal hypoglycemia during the overnight period in children and adolescents with type 1 diabetes in a diabetes camp setting.
RCT Entities:
OBJECTIVE: This study determined the feasibility and efficacy of an automated proportional-integral-derivative with insulin feedback (PID-IFB) controller in overnight closed-loop (OCL) control of children and adolescents with type 1 diabetes over multiple days in a diabetescamp setting. RESEARCH DESIGN AND METHODS: The Medtronic (Northridge, CA) Android™ (Google, Mountain View, CA)-based PID-IFB system consists of the Medtronic Minimed Revel™ 2.0 pump and Enlite™ sensor, a control algorithm residing on an Android phone, a translator, and remote monitoring capabilities. An inpatient study was completed for 16 participants to determine feasibility. For the camp study, subjects with type 1 diabetes were randomized to either OCL or sensor-augmented pump therapy (control conditions) per night for up to 6 nights at diabetescamp. RESULTS: During the camp study, 21 subjects completed 50 OCL nights and 52 control nights. Based on intention to treat, the median time spent in range, from 70 to 150 mg/dL, was greater during OCL at 66.4% (n = 55) versus 50.6% (n = 52) during the control period (P = 0.004). A per-protocol analysis allowed for assessment of algorithm performance with the median percentage time in range, 70-150 mg/dL, being 75.5% (n = 37) for OCL versus 47.6% (n = 32) for the control period (P < 0.001). There was less time spent in the hypoglycemic ranges <60 mg/dL and <70 mg/dL during OCL compared with the control period (P = 0.003 and P < 0.001, respectively). CONCLUSIONS: The PID-IFB controller is effective in improving time spent in range as well as reducing nocturnal hypoglycemia during the overnight period in children and adolescents with type 1 diabetes in a diabetescamp setting.
Authors: Ankush Chakrabarty; Justin M Gregory; L Merkle Moore; Philip E Williams; Ben Farmer; Alan D Cherrington; Peter Lord; Brian Shelton; Don Cohen; Howard C Zisser; Francis J Doyle; Eyal Dassau Journal: J Process Control Date: 2019-02-23 Impact factor: 3.666
Authors: Tamara Spaic; Marsha Driscoll; Dan Raghinaru; Bruce A Buckingham; Darrell M Wilson; Paula Clinton; H Peter Chase; David M Maahs; Gregory P Forlenza; Emily Jost; Irene Hramiak; Terri Paul; B Wayne Bequette; Faye Cameron; Roy W Beck; Craig Kollman; John W Lum; Trang T Ly Journal: Diabetes Care Date: 2017-01-18 Impact factor: 19.112
Authors: Neha S Patel; Michelle A Van Name; Eda Cengiz; Lori R Carria; Eileen M Tichy; Kate Weyman; Stuart A Weinzimer; William V Tamborlane; Jennifer L Sherr Journal: Diabetes Technol Ther Date: 2016-12 Impact factor: 6.118
Authors: Gregory P Forlenza; Dan Raghinaru; Faye Cameron; B Wayne Bequette; H Peter Chase; R Paul Wadwa; David M Maahs; Emily Jost; Trang T Ly; Darrell M Wilson; Lisa Norlander; Laya Ekhlaspour; Hyojin Min; Paula Clinton; Nelly Njeru; John W Lum; Craig Kollman; Roy W Beck; Bruce A Buckingham Journal: Pediatr Diabetes Date: 2017-11-20 Impact factor: 4.866
Authors: Rayhan A Lal; Marina Basina; David M Maahs; Korey Hood; Bruce Buckingham; Darrell M Wilson Journal: Diabetes Care Date: 2019-09-23 Impact factor: 19.112